| Name | Title | Contact Details |
|---|
World-Women To Respond-Disease is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For people with life-threatening blood cancers like leukemia and lymphoma or other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. Every year, thousands of men, women and children get life-threatening diseases like leukemia and lymphoma. Many of them will die unless they get a bone marrow or cord blood transplant from a genetically matched donor. Some people find a match in their family, but 70% do not. These patients depend on the Be The Match to help them find an unrelated donor or cord blood unit. Whether you want to swab your cheek and join Be The Match Registry, make a financial gift or download a photo to show your support on Facebook, you’re in the right place. The best part? Every action you take helps. Be The Match, operated by National Marrow Donor Program (NMDP), is a nonprofit organization dedicated to creating an opportunity for all patients to receive the marrow or umbilical cord blood transplant they need, when they need it.
GRYT Health is a team of cancer survivors and caregivers that helps cancer patients, survivors and caregivers have the info to choose whats right for them at every step of their unique situation.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Lou Ruvo Brain Institute - Cleveland Clinic is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Las Vegas, NV. To find more information about Lou Ruvo Brain Institute - Cleveland Clinic, please visit www.keepmemoryalive.org